Phase II Conjugates of Urolithins Isolated from Human Urine and Potential Role of \( \beta \)-glucuronidases in Their Disposition

Jakub P. Piwowarski, Iwona Stanisławska, Sebastian Granica, Joanna Stefańska, and Anna K. Kiss

Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Faculty of Pharmacy (J.P.P., I.S., S.G., A.K.K.); Department of Pharmaceutical Microbiology, CePT, Medical University of Warsaw (J.S.)

Primary Laboratory of Origin: Medical University of Warsaw, Faculty of Pharmacy
Running Title: Urolithin conjugates. β-glucuronidases and disposition.

Address correspondence to:
Dr. Jakub Piwowarski
Department of Pharmacognosy and Molecular Basis of Phytotherapy
Medical University of Warsaw
Faculty of Pharmacy
Banacha 1
02-097 Warsaw
Poland
Phone: +48 22 5720953
Fax: +48 22 5720942
E-mail: jakub.piwowarski@wum.edu.pl

Number of Text Pages: 30
Number of Tables: 1
Number of Figures: 7
Number of References: 48
Number of Words in Abstract: 250
Number of Words in Introduction: 545
Number of Words in Discussion: 1500
List of Non-Standard Abbreviations:

ETs  ellagitannins
UA   urolithin A
iUA  iso-urolithin A
UB   urolithin B
GiUA iso-urolithin A glucuronide
GUA  urolithin A glucuronide
GUB  urolithin B glucuronide
GSUA urolithin A sulfate-glucuronide
f-MLP N-Formylmethionine-leucyl-phenylalanine
FPR1 formyl peptide receptor-1
MUG  4-methylumbelliferyl-β-D-glucuronide
ABSTRACT

In recent years, many xenobiotics derived from natural products have been shown to undergo extensive metabolism by gut microbiota. Ellagitannins, which are high molecular polyphenols, are metabolized to dibenzo[\(b,d\)]pyran-6-one derivatives - urolithins. These compounds, in contrast with their parental compounds, have good bioavailability and are found in plasma and urine at micromolar concentrations. In vivo studies conducted for ellagitannin-containing natural products indicate their beneficial health effects towards inflammation and cancer, which are associated with the formation of urolithins. However, the great majority of in vitro experiments that have revealed the molecular mechanisms responsible for the observed effects were conducted for urolithin aglycones. These studies are thus incongruent with the results of pharmacokinetic studies that clearly indicate that glucuronide conjugates are the dominant metabolites present in plasma, tissue and urine. The aim of this study was to isolate and structurally characterize urolithin conjugates from the urine of a volunteer who ingested ellagitannin-rich natural products and to evaluate the potential role of \(\beta\)-glucuronidases-triggered cleavage in urolithin disposition. Glucuronides of urolithin A, iso-urolithin A and urolithin B were isolated and shown to be cleaved by the \(\beta\)-glucuronidases released by neutrophils from azurophilic granules upon f-MLP stimulation as well as by \textit{E. coli} standard strains and clinical isolates from patients with urinary tract infections. These results justify the hypothesis that the selective activation of urolithin glucuronides by \(\beta\)-glucuronidase, which are present at high concentrations at inflammation and infection sites and in the microenvironments of solid tumors, could locally increase the concentration of bioactive urolithin aglycones.
Introduction

Accumulating evidence has revealed the diverse effects of the gut microbiota on human health, including nutrition, physiology and host metabolism. In recent years, the metabolic crosstalk between a host and its gut microbiota in modulating the pharmacokinetics and pharmacodynamics of drugs has gained much attention (Klaassen and Cui, 2015; Yip and Chan, 2015). Many xenobiotics derived from food products and medicinal plant materials have been shown to undergo extensive metabolism by gut microbiota, resulting in the formation of small molecular metabolites that not only are more bioavailable than parental compounds but also reveal interesting pharmacological properties (Kieran and Del Rio, 2015). One of the most widely studied gut microbiota metabolites of natural products are the urolithins. These $6H$-dibenzo$[b,d]$pyran-6-one derivatives are produced by gut microbiota from high-molecular-weight polyphenols, namely, the ellagitannins (ETs), which are constituents of various medicinal plants and food products. In contrast with parental ETs, urolithins have good bioavailability and are found in plasma and urine at micromolar concentrations. After absorption, urolithins rapidly undergo Phase II metabolism, resulting in their presence in plasma and tissues mostly in a conjugated form; these metabolites are mainly glucuronides and, to a lesser extent, sulfates. After absorption in the gut, only traces of non-conjugated compounds were detected in bodily fluids, indicating that conjugation has already taken place in the gut epithelium (Gonzalez-Barrio et al., 2010; Gonzalez-Sarrias et al., 2014; Nunez-Sanchez et al., 2014; Mora-Cubillos et al., 2015; Garcia-Villalba et al., 2016; Tomas-Barberan et al., 2016).

In vivo and clinical studies conducted for ET-containing natural products clearly indicate beneficial health effects, especially towards inflammation-associated
diseases and cancer, which are often connected with the formation and absorption of urolithins within the gut (Larrosa et al., 2010a; Larrosa et al., 2010b; Espin et al., 2013; Tomas-Barberan et al., 2016). These results are accompanied by in vitro studies for urolithins that unambiguously confirm their anti-inflammatory and anti-proliferative activities and reveal the molecular mechanisms that are potentially responsible for the observed effects (Gonzalez-Sarrias et al., 2009; Piwowarski et al., 2014a; Piwowarski et al., 2015; Gonzalez-Sarrias et al., 2016).

One important issue that has recently been raised is the inconsistency of in vitro bioactivity results compared with in vivo and clinical pharmacokinetic studies. The great majority of in vitro experiments were conducted for urolithin aglycones, making them incongruent with the results of pharmacokinetic studies that clearly indicate that glucuronide conjugates of urolithins are the dominant metabolites present in plasma, tissues and urine (Tomas-Barberan et al., 2016).

Although urolithin glucuronides are the main metabolites detected in bodily fluids, the highly enzymatically active environment of inflammation and cancer sites should be considered, as they have the potential to trigger structural alterations. One of the most common, abundant enzymes at these sites is β-glucuronidase, which is released from infiltrating inflammatory cells and the lysosomes of necrotic cells (Tranoy-Opalinski et al., 2014). β-glucuronidase is also a characteristic enzyme of Escherichia coli, the bacterial species that is responsible for urinary tract infections, among other disease (Chang et al., 1989).

The aim of the study was to isolate and structurally characterize the urolithin conjugates from the urine of a volunteer after ingestion of ET-rich natural products and to evaluate whether they undergo cleavage under the influence of β-glucuronidases released by human neutrophils, as well as by various E. coli strains.
Materials and Methods

Reference Compounds and Chemicals

Standards of urolithin A (UA), iso-urolithin A (iUA), urolithin B (UB) and urolithin C (UC) were isolated from human gut microbiota cultures using a previously described method (Piwowarski et al., 2016). The purity of examined compounds (≥95%) was confirmed using a UHPLC-DAD-MS^n method. *Lythrum salicaria* herb aqueous extract was prepared as described previously (Piwowarski and Kiss, 2013). The chromatogram obtained with UHPLC-DAD-MS^n method presenting its ellagitannin profile is provided in Supplemental Data Figure S2.

Subject and Dosing Procedure

We chose a healthy volunteer (male, aged 30) based on our previous study, which identified the volunteer as possessing microbiota that produce the most diverse pattern of urolithins (Piwowarski et al., 2016). The volunteer was asked to supplement his diet with products rich in ETs. Pomegranate juice (0.5 L/day), walnuts (30 g/day), hazelnuts (30 g/day) and fresh raspberries (200 g/day) were consumed for five days. The total urine was collected from day 1 to day 5 and stored at -20 °C in a total combined volume of 5.5 L of urine. The study respected the 1964 Declaration of Helsinki for the ethical treatment of human subjects for biomedical research.

UHPLC Analysis of Urine

An SPE Chromabond C_{18} Hydra column (Macherey-Nagel, Germany) was preconditioned with 10 mL of MeOH and 10 mL of H_{2}O. Fifteen mL of urine was applied to the column and washed with 10 mL of H_{2}O before elution with 2 mL of MeOH. The eluate was subjected to UHPLC-DAD-MS^n analysis.
Isolation of Metabolites and Structure Determination

Urine (5.5 L) was concentrated under reduced pressure at 40 °C to 3.0 L and extracted four times with 2 L of EtOAc. The aqueous residue (3.0 L) was subjected to Diaion HP-20 (Supelco) column (40 cm × 5 cm) chromatography and subsequently eluted with 3.0 L of H₂O, 20% MeOH and 100% MeOH. The fraction eluted with 100% MeOH (3.7 g) was chromatographed on a silica gel 60 column (27 cm × 3 cm) eluted with MeOH - CHCl₃ (0:100 → 100:0 v/v in 7 steps) to give 104 fractions pooled into 11 main fractions C₁ – C₁₁. Fraction C₅ (543 mg) was purified using a preparative HPLC system (Shimadzu LC20-AP instrument, Japan, Zorbax SB-C₁₈ 150 mm × 21.2 mm × 5.0 µm, λ₁=254 nm, λ₂=350 nm, flow 9 mL/min, mobile phase: 0.1% HCOOH in water (A) and 0.1% HCOOH in MeCN (B), elution program: 10 – 40% B; 0-40 min) to give urolithin B glucuronide (GUB) (23.80-24.40 min; 25 mg) and UB (31.5-32.0 min; 8 mg). Fractions C₆ (244 mg) and C₉ (37 mg) were chromatographed on a Sephadex LH-20 column (137 cm × 2 cm) and eluted with mixture of MeOH:water (1:1, v/v) to obtain 140 fractions pooled into 9 fractions D₁ – D₉. Fractions D₃ (54 mg) and D₄ (16 mg) were combined and subjected to a preparative HPLC system (elution program: 15 – 20% B; 0-40 min) to give urolithin A glucuronide (GUA) (10.05-12.65 min; 31 mg), iso-urolithin A glucuronide (GiUA) (13.00-14.50 min; 6 mg) and urolithin B glucuronide (GUB) (31.60-33.80 min; 4 mg). Fraction C₇ (1159 mg) was chromatographed on a Sephadex LH-20 column (MeOH:water, 1:1, v/v) to give 297 fractions pooled into 17 fractions E₁ – E₁₇. Fraction E₅ (362 mg) was subjected to a preparative HPLC system (parameters same as for fraction D₃+D₄) to obtain GUA (10.4-12.55 min; 94 mg), GiUA (12.56-14.5 min; 14 mg) and GUB (31.60-33.80 min; 44 mg). Fractions D₂ (22 mg) and E₄ (141 mg) were combined and subjected to a preparative HPLC system (parameters same as for fraction C₅) to give GUB (23.70-
Fraction C₆ (811 mg) was chromatographed on a Sephadex LH-20 column (MeOH:water, 1:1, v/v) to give 241 fractions pooled into 18 fractions F₁ – F₁₈. Fractions F₁₁ (75 mg) and F₁₂ (46 mg) were combined and subjected to a preparative HPLC system (as for fraction C₅) to obtain GUB (23.60-24.10 min; 45 mg) and UB (31.00-31.70 min; 6 mg).

The EtOAc fraction (2.8 g) was chromatographed on a silica gel 60 (Machery-Nagel, Duren, Germany) column (27 cm × 3 cm) eluted with MeOH - CHCl₃ (0:100 → 100:0 v/v in 9 steps) to give 140 fractions pooled into 10 main fractions A₁ – A₁₀. Fractions A₂+A₃ (91.7 mg) contained UB as the major compound, which was purified using preparative HPLC (31.50-32.00 min, 4 mg).

¹H and ¹³C NMR spectra were recorded at 25 °C on a VARIAN VNMRS instrument (300 MHz for ¹H and 75 MHz for ¹³C NMR). DMSO-d₆ was used as a solvent. Chemical shifts (δ) are reported in ppm, and coupling constants (J) are reported in Hz. The assignments were based on HSQC and HMBC experiments.

**Gut microbiota ex vivo metabolism**

Evaluation of the ex vivo metabolism of ellagitannins by the volunteer’s gut microbiota was performed as described previously (Piwowarski et al., 2014b). To acquire anaerobic conditions, a brain heart infusion (BHI), (DIFCO, Detroit, MI, USA) was boiled and immediately cooled before the experiment. Forty mg of *Lythrum salicaria* L. extract (phytochemically standardized ET source) was dissolved in 1 mL of distilled water and sterilized by filtration through an Ophtalsart hydrophilic syringe filter (0.2 mm) (Sartorius Stedim Biotech GmbH, Germany). One mL of 10% fecal slurry in BHI and 0.5 mL of extract solution were added to 8.5 mL of BHI. The batch cultures were incubated in a sealed container under anaerobic conditions using GENbox anaer sachets (bioMerieux, France) at 37 °C. After 24 h, the batch culture...
was extracted three times with 10 mL of diethyl ether. The organic layers were evaporated to dryness and re-dissolved in 500 µL of MeOH for UHPLC-DAD-MS\textsuperscript{n} analysis.

**Neutrophils Isolation**

Peripheral venous blood was taken from four healthy human donors (males, 20-35 years old) at the Warsaw Blood Donation Centre. Donors did not smoke or take any medication. They were clinically confirmed to be healthy, and routine laboratory tests showed values within the normal range. The study conformed to the principles of the Declaration of Helsinki. Neutrophils were isolated with a standard method of dextran sedimentation and subsequent hypotonic lysis of erythrocytes and centrifugation in a Ficoll Hypaque gradient (Piwowarski et al., 2014a). The purity of neutrophils was >97%, and viability as measured by trypan blue exclusion was >98%.

Deglucuronidation assay: After isolation, neutrophils were resuspended in HBSS (6×10\textsuperscript{5} cells/mL) primed with cytochalasin B (5 µg/mL) for 5 min and stimulated with f-MLP (1 µM) for 10 min. The neutrophils were centrifuged (2,000 rpm; 10 min; 4 °C). The supernatant was acidified with lactic acid to pH=5.2 and incubated with GiUA, GUA and GUB at a final concentration of 50 µM. After 24 h, 300 µL reaction mixture was mixed with 400 µL MeOH, subjected to an ultrasonication for 5 min and centrifuged (14000 g, 10 min). The hydrolysis of glucuronides was monitored using a UHPLC-DAD-MS\textsuperscript{n} method. The amount of released β-glucuronidase in supernatants was determined using a human β-glucuronidase ELISA Kit (Wuhan Fine Biological Technology Co., Ltd, Wuhan, China) according to the manufacturer’s instructions.
Deglucuronidation in *E. coli in vitro* cultures

*E. coli* NCTC 10538, ATCC 25922 strains and clinical isolates (C1-C7) were streaked over a Trypticase Soy Agar plate (Becton Dickinson) and incubated for 24 h at 37 °C. A single colony was used to inoculate 10 mL of BHI, which was incubated for 24 h at 37 °C. To 240 µL of culture, 60 µL of the respective glucuronide solution in PBS was added (final concentration of glucuronide: 50 µM) and incubated for 24 h at 37 °C. Next, 400 µL of MeOH was added to 250 µL of culture, subjected to ultrasonication and centrifuged (14000 g, 10 min). The hydrolysis of glucuronides was monitored using a UHPLC-DAD-MS\(^n\) method.

**Chromatographic methods**

UHPLC-DAD-MS\(^n\) analyses were performed using a UHPLC-3000 RS system (Dionex, Germany) with DAD detection and an AmaZon SL mass spectrometer with the ESI interface (Bruker Daltonik GmbH, Germany). A Zorbax SB-C\(_{18}\) (150 mm x 2.1 mm x 1.9 µm) (Agilent, USA) column was used. The mobile phase consisted of 0.1% HCOOH in water (A) and 0.1% HCOOH in MeCN (B). The gradient was: 0–5 min 0% B, 5–15 min 0–10% B, 15–25 min 10–20% B and 25–35 min 20–30% B, 35–45 min 30–50% B, 45–50 min 50–100% B and 50–60 min 100% B. The column temperature was maintained at 25 °C, and the flow rate was 0.200 mL/min. The LC eluate was introduced into the ESI interface without splitting, and compounds were analyzed in the negative and positive ion modes with the following settings: nebulizer pressure of 40 psi; drying gas flow rate of 9 L/min; nitrogen gas temperature of 300 °C; and capillary voltage of 4.5 kV. The mass scan ranged from 100 to 2200 \(m/z\). UV spectra were recorded from 200–400 nm. The presence of UA, iUA, UB and UC was confirmed by comparing retention times and UV and \(m/z\) spectra with authentic
samples. Other compounds were tentatively assigned based on their chromatographic properties, namely, UV and MS spectra.

**Statistical analysis**

The results are shown as the mean values ± SEM. The statistical significance of differences between means was determined by one-way ANOVA. For comparison of results between the groups, Tukey’s *post hoc* test was used. Results with *p*-value < 0.05 were considered statistically significant. All analyses were performed using Statistica 10 software.

**Results**

**Profile of urinary metabolites.** UHPLC-DAD-MS/MS analysis has shown that the regular weekly intake of ET-rich products results in secretion of Phase II conjugates of urolithins in urine (Fig. 2A). Metabolites were identified based on their retention times and UV and MS/MS data. The major metabolite was **GUA**, which gave a pseudomolecular ion at *m/z* = 403 and an ion fragment at 227 representing a neutral loss of 176 amu that is characteristic of glucuronic acid. **GiUA**, with a similar pseudomolecular ion and fragmentation pattern, was distinguished from **GUA** based on UV spectra (Gonzalez-Barrio et al., 2011). **GUB** gave a pseudomolecular ion at *m/z* = 387 and a fragment ion at 211. Small amounts of urolithin A sulfate-glucuronide (GSUA) were detected at *m/z* = 483 and the MS² ion at 307 (neutral loss of 176 amu) which fragmented to 227 (characteristic for neutral sulfate loss of 80 amu). Apart from Phase II conjugates, small amounts of iUA, UA and UB were also detected.

**Metabolite isolation and structural determination.** By means of liquid-liquid extraction, column chromatography and preparative high-performance liquid
chromatography, three major glucuronide metabolites were isolated from human urine—GiUA, GUA, GUB (Fig. 1)—as was UB. The structures were determined using $^1$H, $^{13}$C NMR, HSQC and HMBC spectra (Table 1). All metabolites were identified as β-anomers based on the anomeric H-1 signal appearing at δ 5.0 as a doublet, with a coupling constant near 7 Hz (Pearson et al., 2005). The downfield shift of H2 and H4 in the GiUA spectrum, compared to to its aglycone (Piwowarski et al., 2016), indicates glucuronidation of the OH group at C3. The analogous shifts were observed for H2 and H4 of urolithin A 3-O-glucuronide and H7 and H9 of urolithin A 8-O-glucuronide. The total amounts of obtained compounds were 20 mg of GiUA, 125 mg of GUA, 139 mg of GUB and 18 mg of UB. GUA was isolated as a mixture of urolithin A-3-O-glucuronide and urolithin A-8-O-glucuronide as revealed by NMR spectra, which have shown two sets of proton (Fig. 3) and carbon signals. It was impossible to separate these two isomers using available chromatographic methods. However, complete proton and carbon assignments were performed based on 2D NMR spectra (Table 1).

**Gut microbiota ex vivo metabolism.** In all, iUA, UA, UB, and UC were determined in the volunteer’s gut microbiota cultures (Fig. 2B). Their identities were confirmed by comparison of retention times, UV and MS data with standard substances. The most abundant peak was observed for iUA, while only small amounts of UA were detected.

**Deglucuronidation by human neutrophils.** Neutrophils isolated from human peripheral venous blood were primed with cytochalasin B and subsequently stimulated with f-MLP to release the azurophilic granules containing β-glucuronidase. The supernatant pH was adjusted to 5.2 – which is known to be an optimal value for
enzyme activity (Ho, 1985). Incubation of \textbf{GiUA}, \textbf{GUA} and \textbf{GUB} with supernatants resulted in enzymatic cleavage of β-glycosidic bonds and release of the respective aglycones (Fig. 4A and 5). The deglucuronidation process was significantly enhanced when neutrophils were stimulated with cytochalasin B and f-MLP in comparison to untreated cells. When pH was adjusted beyond the optimal values (pH=7.2 in the case of HBSS without lactic acid and pH=3.5 when excessive acidification was applied), deglucuronidation was not observed (data not shown). To evaluate whether β-glucuronidase is responsible for the cleavage, its concentration was determined using an ELISA test. Significantly higher enzyme protein concentrations in supernatants were observed upon stimulation. In addition, differences in the amounts of f-MLP-triggered enzyme release were observed between blood donors (D1-D4) that were strictly correlated with the extent of deglucuronidation (Fig. 4B). No significant differences in the compounds’ susceptibility to enzymatic cleavage were observed.

**Deglucuronidation in \textit{E. coli} cultures.** Two reference \textit{E. coli} strains, NCTC 10538 and ATCC 25922, and 7 clinical isolates (C1-C7) obtained from patients suffering from urinary tract infections were used for examinations. Cultures in Fluorocult VRB Agar plates (Merck) revealed that the strains expressed different abilities to hydrolyze 4-methylumbelliferyl-β-D-glucuronide (MUG) (Fig. 6). The most intense blue fluorescence from free 4-methylumbelliferone was observed in the \textit{E. coli} C1 strain, while \textit{E. coli} NCTC 10538 and C6 showed no fluorescence. Incubation of \textbf{GiUA}, \textbf{GUA} and \textbf{GUB} with selected \textit{E. coli} strains and isolates resulted in deglucuronidation and release of the respective aglycones (Fig. 7, Supplemental Data Figure S1). No hydrolysis was observed when compounds were incubated in BHI medium without bacteria inoculation. The most active strain was C1, which was
also the most potent in MUG cleavage. The non-MUG-degrading *E. coli* isolate C6 only hydrolyzed the tested glucuronides to a small extent. Comparison of cleavage rates for each glucuronide revealed that in the case of clinical isolates, GUB was the most susceptible for degradation.

**Discussion**

The chosen volunteer was assigned as metabotype B (producing iUA, UA, and UB) (Tomas-Barberan et al., 2014). In addition to Phase II metabolites, the respective aglycones were also detected in urine. They were not only found when total collected urine was analyzed (Fig. 2A) but also when samples were analyzed immediately after collection (data not shown), which excludes the possibility of their formation through storage-triggered hydrolysis. The most abundant metabolite was GUA, while *ex vivo* cultures of the volunteer’s gut microbiota showed the reverse pattern, with significant dominance of iUA. This observed iUA dominance was in concordance with previous studies conducted on single ETs using the volunteer’s gut microbiota (see volunteer D3 in our previous paper Piwowarski et al., 2016). This discrepancy could be explained by different metabolic activity in gut microbiota *in vivo* and *ex vivo* or by differences in the metabolic and/or elimination pathways between UA and iUA. Although the volunteer’s microbiota were able to produce UC, no phase II metabolites of this compound were detected in urine.

Phase II metabolites of urolithins were isolated from human urine and their structures were fully described based on the NMR spectra. NMR data for GUA and GUB were in concordance with $^1$H spectra for compounds obtained through chemical synthesis (Lucas et al., 2009; Gonzalez-Sarrias et al., 2013). The 1D and 2D NMR spectra allowed full assignment of the $^1$H and $^{13}$C signals for the first time. The
formation of two GUA regioisomers, i.e., urolithin A 3-O-glucuronide and urolithin A-8-O-glucuronide, was thus fully confirmed in vivo. As in previously described methods for GUA biosynthesis, we were unable to separate the two GUA isomers (Gimenez-Bastida et al., 2012), because they co-eluted in the applied column chromatography resins and the analytical RP18 UHPLC column. However, using 2D NMR experiments, we were able to distinguish two series of signals. Based on comparison of their intensities, it can be postulated that glucuronidation at position 8 is favorable. In the future, methods to separate these compounds should be developed. However, this mixture can still be used in bioassays, as it potentially reflects the actual proportion of these metabolites in bodily fluids. The identification presented here is in concordance with previous studies using HPLC-TOFMS-SPE-NMR analysis of urine from patients who ingested tea (van der Hooft et al., 2012).

For the first time GiUA, which was found only as the 3-O-glucuronide, was isolated from human urine. The developed method yields significant amounts of Phase II metabolites of urolithins, which can be then applied to evaluate the in vivo effects and mechanisms of ET microbiota metabolites. The isolation of GiUA is of particular importance, as 10-50% of population has been identified as iUA producers (Tomas-Barberan et al., 2014). This compound has not previously been synthesized or isolated from biological fluids.

The concentration of Phase II urolithin metabolites in human plasma and urine can reach 35 µM and 100 µM respectively, while aglycones are present in significantly lower concentrations – 0.005 µM and 10 µM respectively (Tomas-Barberan et al., 2016). In prostate and colon tissues urolithin glucuronides were found at nanomolar concentrations (Gonzalez-Sarrias et al., 2010). Both the aglycones and their conjugates ranged from 4.8 and 507.3 ng/g in human colon tissues.
tissue samples (Nunez-Sanchez et al., 2014). The administration of UA to rats showed that the distribution of this compound and its conjugated metabolites among different organs reached concentrations up to 1050 ng/g (Seeram et al., 2007).

Although urolithin conjugates were clearly shown to dominate in plasma, tissues and urine following the administration of ET-rich natural products, the majority of in vitro studies have focused on non-conjugated molecules. Only a few studies investigate urolithin Phase II metabolites, the majority of which have shown significant in vitro and in silico decreases in activity for conjugated compounds. The Phase-II metabolism of urolithins in different cell lines is considered a mechanism of cancer cells resistance against urolithins, due to their conversion to glucuronide conjugates, which were shown to exert significantly lower anti-proliferative activity (Adams et al., 2010; Dellaflora et al., 2013; Gonzalez-Sarrias et al., 2014; Gonzalez-Sarrias et al., 2015; Larrosa et al., 2006; Sala et al., 2015). This is the first report of a reversed process of deglucuronidation. Differences in anti-inflammatory activity between GUA and UA were only shown by Gimenez-Bastida et al., 2012, while urolithin methylation was shown to lead to significant activity loss or decrease (Piwowarski et al., 2014a).

In vitro and in vivo studies clearly underline the two major activities of urolithins: anti-inflammatory and anti-neoplastic (Tomas-Barberan et al., 2016). Additionally, urolithin A was recently shown to improve mitochondrial and muscle function due to the enhancement of mitophagy (Ryu et al., 2016). Nonetheless, low plasma and tissue concentrations of non-conjugated urolithins caused by intensive Phase II metabolism render the activities determined for aglycones in vitro inconsistent with in vivo data.
Numerous pathological conditions, including inflammatory processes and tumors, are known to be associated with significantly increased levels of extracellular β-glucuronidase. Human β-glucuronidase is a lysosomal enzyme that accumulates at inflammation sites and in tumor microenvironments due to release from infiltrating neutrophils and macrophages as well as necrotic cells (Tranoy-Opalinski et al., 2014). Mitochondrial respiration defects observed in inflamed and neoplastic tissues lead to aerobic glycolysis—also known as the Warburg effect—resulting in pH decreases due to elevated lactic acid production that creates optimal conditions for β-glucuronidase activity (Warburg, 1956a; Warburg, 1956b; Palsson-McDermott and O'Neill, 2013). As a result, autophagy impairment leads to mitochondrial dysfunction that induces β-glucuronidase activity (Ishisaka et al., 2013), while damaged mitochondria, similar to bacteria, release formyl peptides that can signal using formyl peptide receptor-1 (FPR1) to trigger an immune response (Sun et al., 2016).

We have clearly shown that urolithin conjugates are cleaved by β-glucuronidase, which is released by neutrophils from azurophilic granules upon stimulation of FPR1. The optimum pH, obtained by acidification with lactic acid, was necessary for enzymatic cleavage, as it was not observed in either the environment of pure HBSS or acidified to pH=3.5. Previous studies conducted for luteolin glucuronide have revealed that its deconjugation is triggered by stimulated neutrophils. An increased ratio of aglycone/glucuronide was also observed in the plasma of LPS-treated rats (Shimoi et al., 2001). The β-glucuronidase released by macrophages was shown to be essential for activation of quercetin glucuronide conjugates. Its enzymatic activity, which requires acidic pH, was promoted by increased secretion of lactate in response to mitochondrial dysfunction (Kawai, 2014).
The role of selective deconjugation within neoplastic tissues has attracted considerable attention. Since high levels of β-glucuronidase can be found in most solid tumors, a wide number of structurally diverse glucuronide prodrugs have been designed with the aim of enhancing the selectivity of cancer chemotherapy. (Tranoy-Opalinski et al., 2014).

Although the highest concentration of urolithin Phase II metabolites were observed in urine, no studies have yet been conducted regarding the impact of these compounds on ailments associated with urinary tract disorders. Uropathogenic Escherichia coli (UPEC) is the main cause of urinary tract infections, which produces significant amounts of β-glucuronidase (Vinacur et al., 1974; Helander and Dahl, 2005; McLellan and Hunstad, 2016). We have shown that standard strains of E. coli, as well as clinical isolates from patients with urinary tract infections, were capable of urolithin glucuronides cleavage. Previous studies conducted for the Phase II metabolites of hydroquinone have shown that E. coli cleaved hydroquinone conjugates and liberated toxic free hydroquinone, which is known to possess antibacterial activity (Siegers et al., 2003). To date, no studies regarding the urolithin effects of urinary tract disorders, E. coli viability and virulence factors have been conducted. Nevertheless, deconjugation of urolithin glucuronides by E. coli β-glucuronidase revealed here indicates the need for examination of both conjugated and non-conjugated urolithins in future studies on the influence of orally administered ET-containing natural products on processes associated with urinary tract infections.

The dominance of urolithins of plasma, tissues and urine glucuronide conjugates is potent, as they release their aglycones directly in inflamed and neoplastic tissues due to enhanced β-glucuronidase activity. The release of free aglycones is also possible within urinary tracts infected with β-glucuronidase-
producing *E. coli* strains. Strong biological activities, such as the anti-neoplastic and anti-inflammatory activities already described for non-conjugated urolithins (Tomas-Barberan et al., 2016), make intensive detoxification through Phase II metabolism plausible. This process could be responsible for prevention of the impact of urolithins on biochemical processes throughout the entire organism. The conjugation of these pharmacologically active metabolites can be thus seen as a beneficial process, especially considering the formation of these compounds by gut microbiota from ETs that are widely distributed in various food products. It can be hypothesized that the selective activation of urolithin glucuronides by β-glucuronidase present at high concentrations at the inflammation site and in the microenvironments of most solid tumors could only locally increase the concentration of bioactive urolithin aglycones. This action can prevent their impact on cellular processes within healthy tissues. To fully support the stated hypothesis, the observed deconjugation should be further confirmed in *in vivo* studies. However, the presented results provide first new insights into understanding urolithin disposition.

**Authorship contributions:**

Participated in research design: Piwowarski, Stefańska, Kiss

Conducted experiments: Piwowarski, Stanisławska

Contributed new reagents or analytic tools: Granica, Piwowarski

Performed data analysis: Piwowarski

Wrote or contributed to the writing of the manuscript: Piwowarski, Stanisławska
References


Nunez-Sanchez MA, Garcia-Villalba R, Monedero-Saiz T, Garcia-Talavera NV, Gomez-Sanchez MB, Sanchez-Alvarez C, Garcia-Albert AM, Rodriguez-Gil


Tomas-Barberan FA, Gonzalez-Sarrias A, Garcia-Villalba R, Nunez-Sanchez MA, Selma MV, Garcia-Conesa MT, and Espin JC (2016) Urolithins, the rescue of 'old' metabolites to understand a 'new' concept: metabotypes as a nexus between phenolic metabolism, microbiota dysbiosis and host health status. *Mol Nutr Food Res.*


Footnotes

The project was financially supported by a Polish Ministry of Science and Higher Education research grant, Iuventus Plus [IP2015 062274]. J.P.P. was financially supported by a Foundation for Polish Science START scholarship [START 84.2016]. The project was performed using Centre for Preclinical Research and Technology infrastructure financed by the European Regional Development Fund within the “Innovative Economy” Operational Programme for 2007–2013.

Reprint requests should be directed to:

Dr. Jakub Piwowarski
Department of Pharmacognosy and Molecular Basis of Phytotherapy
Medical University of Warsaw
Faculty of Pharmacy
Banacha 1
02-097 Warsaw
Poland
Legends for Figures:

**Fig. 1.** Chemical structures of isolated urolithin Phase II metabolites

**Fig. 3.** $^1$H NMR spectra of urolithin A-3-O-glucuronide and urolithin A-8-O-glucuronide mixture (GUA).

**Fig. 4.** (A) Cleavage of GiUA, GUA and GUB by $\beta$-glucuronidase released by human neutrophils obtained from four donors (D1-D4) and assayed in duplicate. (B) Comparison of release of $\beta$-glucuronidase protein between f-MLP-stimulated (ST) and non-stimulated (NST) neutrophils. Statistical significance: * $p < 0.05$, ** $p < 0.01$ versus respective non-stimulated controls.

**Fig. 5.** Chromatograms presenting cleavage of GiUA, GUA and GUB in acidified supernatants (pH= 5.2) obtained from neutrophils isolated from D4 stimulated with f-MLP.

**Fig. 6.** Cultures of tested *E. coli* standard strains and clinical isolates (C1-C7) in Fluorocult VRB Agar plates visualized with UV light at 366 nm.

**Fig. 7.** Deglucuronidation of GiUA, GUA and GUB by $\beta$-glucuronidase released by *E. coli* standard strains and clinical isolates (C1-C7). Three separate experiments were conducted in duplicate. Statistical significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus other glucuronides within the group. Chromatograms are provided in Supplemental Data Figure S1.
### Tables:

**Table 1.** NMR spectroscopic data (300 MHz, DMSO-$d_6$) for GiUA, GUA and GUB.

<table>
<thead>
<tr>
<th>Iso-Urolithin A 3-O-Glucuronide</th>
<th>Urolithin A 8-O-Glucuronide</th>
<th>Urolithin A 3-O-Glucuronide</th>
<th>Urolithin B 3-O-Glucuronide</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\delta_H$</td>
<td>$\delta_C$</td>
<td>$\delta_H$</td>
<td>$\delta_C$</td>
</tr>
<tr>
<td>1</td>
<td>8.12 (d, $J=8.9$ Hz)</td>
<td>125.14</td>
<td>8.09 (d, $J=8.9$ Hz)</td>
</tr>
<tr>
<td>2</td>
<td>7.05 (o)</td>
<td>113.83</td>
<td>6.83 (dd, $J=8.7$, 2.4 Hz)</td>
</tr>
<tr>
<td>3</td>
<td>159.05</td>
<td>10.24 (s) (OH)</td>
<td>159.20</td>
</tr>
<tr>
<td>4</td>
<td>7.07 (o)</td>
<td>104.29</td>
<td>6.75 (d, $J=2.4$ Hz)</td>
</tr>
<tr>
<td>4a</td>
<td>152.57</td>
<td>151.37</td>
<td>150.55</td>
</tr>
<tr>
<td>6</td>
<td>160.61</td>
<td>160.35</td>
<td>160.39</td>
</tr>
<tr>
<td>6a</td>
<td>112.42</td>
<td>120.08</td>
<td>120.77</td>
</tr>
<tr>
<td>7</td>
<td>8.08 (d, $J=8.7$ Hz)</td>
<td>132.97</td>
<td>7.74 (d, $J=2.7$ Hz)</td>
</tr>
<tr>
<td>8</td>
<td>7.02 (o)</td>
<td>117.60</td>
<td>156.15</td>
</tr>
<tr>
<td>9</td>
<td>164.30</td>
<td>7.56 (dd, $J=8.8$, 2.7 Hz)</td>
<td>124.95</td>
</tr>
<tr>
<td>10</td>
<td>7.53 (d, $J=2.1$ Hz)</td>
<td>107.23</td>
<td>8.23 (d, $J=9.0$ Hz)</td>
</tr>
<tr>
<td>10a</td>
<td>137.28</td>
<td>129.77</td>
<td>126.26</td>
</tr>
<tr>
<td>10b</td>
<td>111.52</td>
<td>112.46</td>
<td>112.46</td>
</tr>
</tbody>
</table>

| Glur1 | 5.23 (d, $J=7.2$ Hz) | 99.97 | 5.22 (d, $J=7.2$ Hz) | 100.25 | 5.21 (d, $J=7.3$ Hz) | 99.60 | 5.15 (d, $J=6.8$ Hz) | 99.88 |
| Glur2 | 3.32 (o) | 73.32 | 3.30-3.45 (o) | 72.99 | 3.30-3.45 (o) | 72.87 | 3.34 (o) | 73.14 |
| Glur3 | 3.35 (o) | 76.18 | 3.30-3.45 (o) | 75.74 | 3.30-3.45 (o) | 75.54 | 3.38 (o) | 75.88 |
| Glur4 | 3.42 (o) | 71.76 | 3.30-3.45 (o) | 71.32 | 3.30-3.45 (o) | 71.29 | 3.40 (o) | 71.69 |
| Glur5 | 4.03 (d, $J=9.2$ Hz) | 75.79 | 3.99 (d, $J=9.2$ Hz) | 75.46 | 4.02 (d, $J=9.2$ Hz) | 75.34 | 4.02 (d, $J=9.2$ Hz) | 75.56 |
| Glur6 | 170.56 | 170.05 | 170.08 | 170.71 |

s- singlet, d- doublet, dd- doublet of doublets, t- triplet, o- overlapped signals
Figure 3

- Urolithin A-8-O-glucuronide
- Urolithin A-3-O-glucuronide
- Overlapped signals

f1 (ppm)
Figure 5